Bruker to Acquire NanoString Technologies for $392.6M in Cash
The deal is expected to close in early May, subject to bankruptcy court approval and other customary conditions.
Population Genetic Screening Would Reveal Patients With Underdiagnosed Disorders, Study Suggests
Researchers developed a data-driven, genomics-first strategy for empirically determining which genes to select for population screening efforts.
23andMe CEO Proposes Taking Company Private
Anne Wojcicki currently owns more than 20 percent of outstanding shares, granting her nearly 50 percent of the company's full voting power.
Multigene Urine Test for High-Grade Prostate Cancer Validated in Clinical Study
Offered by LynxDx, the 18-gene test is intended to evaluate men with elevated PSA levels to help determine if they are at risk for aggressive prostate cancer.
The Shenzhen-based company booked RMB 4.35 billion ($600.9 million) in revenues last year, compared with RMB 7.05 billion in 2022.